Effect of Switching Tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in Patients with COPD: The Difference of Adverse Events and Usability Between Inhaler Devices

Asakura, Yuka; Nishimura, Naoki; Maezawa, Kayoko; Terajima, Tomomi; Kizu, Junko; Chohnabayashi, Naohiko

doi:10.1089/jamp.2011.0941

Cited by 22 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although they are pharmacologically inert, they can produce a cold sensation that may cause the patient to stop inhaling 24. SMIs do not require propellants,41 and excipients are minimized. The delivery of the drug as a mist aerosol avoids the cool sensation from evaporating gases that can be experienced with pMDIs 16.…”

Section: Requirements Of the “Ideal” Inhalermentioning

confidence: 99%

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®

Dekhuijzen¹,

Lavorini²,

Usmani³

2016

PPA

View full text Add to dashboard Cite

Poor inhaler technique hampers the efficacy of drug therapy in asthma and chronic obstructive pulmonary disease. Not only does this affect individual patient care, but it also impacts on the wider health care economics associated with these conditions. Treatment guidelines recommend a systematic approach to drug class selection; however, standardization of inhaler selection is currently difficult owing to the complexity of the interaction between the inhaler device and the patient. Specifically, individual patient preference can influence how successful a treatment is overall. This article reviews inhaler devices from the patient perspective, with a particular focus on the dry powder inhaler HandiHaler® and Respimat® Soft Mist™ Inhaler. It discusses factors that influence device preference and treatment compliance and reviews tools that can aid health care professionals to better match inhaler devices to individual patients’ needs.

show abstract

Section: Requirements Of the “Ideal” Inhalermentioning

confidence: 99%

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®

Dekhuijzen¹,

Lavorini²,

Usmani³

2016

PPA

View full text Add to dashboard Cite

show abstract

“…In TABLE 7, the author has reported some studies where LAMA/device systems are compared in terms of preference, usability, inhaler use, satisfaction with use and willingness to continue the inhaler use [49,75,135,[142][143][144][145][146][147][148][149][150][151][152][153][154][155][156][157]. Unfortunately, these outcomes were assessed in various ways, ranging from a simple question to non-validated and validated proprietary questionnaires.…”

Section: Devicementioning

confidence: 99%

Long-acting muscarinic antagonists

Melani

2015

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment. Long-acting muscarinic antagonists (LAMAs) are a major class of inhaled bronchodilators. Some LAMA/device systems with different characteristics and dosing schedules are currently approved for maintenance therapy of COPD and a range of other products are being developed. They improve lung function and patient-reported outcomes and reduce acute bronchial exacerbations with good safety. LAMAs are used either alone or associated with long-acting β₂-agonists, eventually in fixed dose combinations. Long-acting β₂-agonist/LAMA combinations assure additional benefits over the individual components alone. The reader will obtain a view of the safety and efficacy of the different LAMA/device systems in COPD patients.

show abstract

“…In addition, successful drug delivery to the lungs (as determined by a physician) is associated with patient satisfaction with their inhaler device; satisfaction promotes long-term compliance with respiratory maintenance therapy and is linked to improved clinical outcomes [1,3,[45][46][47]. Assessments conducted during clinical trials and studies using self-report instruments [including simple surveys specific to Respimat Ò , the validated Patient Satisfaction and Preference Questionnaire (PASAPQ) and the Handling Questionnaire (an investigational tool)] have suggested that patients with COPD or asthma find Respimat Ò easy to operate [3,45,[48][49][50][51][52][53] and prefer this inhaler over other types of device, such as pMDIs or DPIs [3,[49][50][51][52]54].…”

Section: Respimatmentioning

confidence: 99%

The Respimat® Development Story: Patient-Centered Innovation

et al. 2017

View full text Add to dashboard Cite

The Respimat Ò Soft Mist TM Inhaler represents a unique delivery system for respiratory medications, using an innovative concept with major technological advancements made during prototype development. The Respimat Ò concept was driven by the intent to solve problems associated with existing inhaler devices for patient use. The following core aims were achieved: (1) avoiding propellants while reducing requirements for patient coordination and inspiratory effort; (2) optimizing drug delivery to the lungs, and; (3) improving the patients' experience of taking their inhaled medication. The RespimatÒ inhaler is the first-marketed, pocket-sized inhaler to successfully generate a metered dose of therapeutic aerosol mist from an aqueous solution. Patient feedback has strongly influenced the evolution of the Respimat Ò inhaler design and instructions for use. The availability of Respimat Ò augments options for clinicians and patients seeking to choose an inhaler that can effectively and consistently deliver respiratory medication to targeted areas of the lung. In many countries worldwide, Respimat Ò is available for the administration of tiotropium, olodaterol (and tiotropium/olodaterol in fixed-dose combination), ipratropium/fenoterol, and ipratropium/albuterol. Funding: Boehringer Ingelheim.

show abstract

Effect of Switching Tiotropium HandiHaler^® to Respimat^® Soft Mist^™ Inhaler in Patients with COPD: The Difference of Adverse Events and Usability Between Inhaler Devices

Abstract: There was no major problem in switching from tiotropium HandiHaler to Respimat. Respimat and HandiHaler showed similar effects and usability. However, we should be aware of cough just after inhalation with Respimat.

Cited by 22 publications

References 6 publications

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat<sup>® </sup>or HandiHaler<sup>®</sup>

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat<sup>® </sup>or HandiHaler<sup>®</sup>

Long-acting muscarinic antagonists

The Respimat® Development Story: Patient-Centered Innovation

Contact Info

Product

Resources

About

Effect of Switching Tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in Patients with COPD: The Difference of Adverse Events and Usability Between Inhaler Devices

Abstract: There was no major problem in switching from tiotropium HandiHaler to Respimat. Respimat and HandiHaler showed similar effects and usability. However, we should be aware of cough just after inhalation with Respimat.

Cited by 22 publications

References 6 publications

Patients&rsquo; perspectives and preferences in the choice of inhalers: the case for Respimat<sup>&reg; </sup>or HandiHaler<sup>&reg;</sup>

Patients&rsquo; perspectives and preferences in the choice of inhalers: the case for Respimat<sup>&reg; </sup>or HandiHaler<sup>&reg;</sup>

Long-acting muscarinic antagonists

The Respimat® Development Story: Patient-Centered Innovation

Contact Info

Product

Resources

About

Effect of Switching Tiotropium HandiHaler^® to Respimat^® Soft Mist^™ Inhaler in Patients with COPD: The Difference of Adverse Events and Usability Between Inhaler Devices

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat<sup>® </sup>or HandiHaler<sup>®</sup>

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat<sup>® </sup>or HandiHaler<sup>®</sup>